Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Buschle is active.

Publication


Featured researches published by Michael Buschle.


Journal of Molecular Medicine | 1997

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.

Georg Stingl; Eva-B. Bröcker; Roland Mertelsmann; Klaus Wolff; Susanne Schreiber; Eckhart Kämpgen; Achim Schneeberger; Jiri Trcka; U. Brennscheidt; H. Veelken; Max L. Birnstiel; Kurt Zatloukal; Gerd Maass; Ernst Wagner; Michael Buschle; E.-R. Kempe; H. A. Weber; Thor Voigt

Vienna: 30 November 1994 Würzburg: 7 February 1995 Freiburg: 7 February 1995 Registration of protocol with state authority AMB: 7 November 1994 Bfarm: 30 October 1994 Registration of product with federal authority (Paul-Ehrlich-Institut) 30 December 1994 Therapeutic gene Human interleukin-2 Regulatory element(s) CMV promoter Vector constructed by Institute of Molecular Pathology, Vienna, Austria Vector produced by Bender & Co., Vienna, Austria Transfer method Receptor-mediated, adenovirus enhanced gene transfer (transferinfection) in vitro Packaging cells N/A Target cells Autologous human malignant melanoma cells Indication Metastatic malignant melanoma (stage IV) First patient enrolled 15 December 1994 (Vienna) Patient number 12 evaluable patients Expected accrual rate 3 patients per month


Gene Therapy | 1994

Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus.

Matt Cotten; Adam Baker; Mediyha Saltik; Ernst Wagner; Michael Buschle


Archive | 1997

Pharmaceutical composition for immunomodulation based on peptides and adjuvants

Walter Schmidt; Max L Prof Dr Birnstiel; Peter Steinlein; Michael Buschle; Tamás Schweighoffer


Archive | 1994

Process for preparing cancer vaccines

Max L. Birnstiel; Michael Buschle; Matthew Cotten; Gerhard Maas; Christian Plank; Gotthold Schaffner; Walter Schmidt; Ernst Wagner; Kurt Zatloukal


Archive | 1995

Method for introducing nucleic acids into higher eukaryotic cells

Michael Buschle; Ernst Wagner; Wolfgang Zauner


Gene Therapy | 1996

Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines

Schweighoffer T; Schmidt W; Michael Buschle; Birnstiel Ml


Pathology Research and Practice | 1994

Genetic modification of cells by receptor-mediated adenovirus-augmented gene delivery: a new approach for immunotherapy of cancer.

Kurt Zatloukal; Achim Schneeberger; Manfred Berger; Frieder Koszik; Walter Schmidt; Ernst Wagner; Matthew Cotten; Michael Buschle; Gerd Maass; Georg Stingl


Archive | 1994

Transfection of eukaryotic cells with nucleic acid

Michael Buschle; Ernst Wagner; Wolfgang Zauner


Archive | 1994

Synthetic virus-like gene delivery systems

Ernst Wagner; Michael Buschle; Matt Cotten; Christian Plank; Wolfgang Zauner; Max L. Birnstiel


Archive | 1997

PROCESS FOR INTRODUCING NUCLEIC ACIDS INTO EUCARYOTIC CELLS

Matthew Cotten; Adam Baker; Michael Buschle; Ernst Wagner; Tamás Schweighoffer

Collaboration


Dive into the Michael Buschle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matt Cotten

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Georg Stingl

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Kurt Zatloukal

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Max L. Birnstiel

Research Institute of Molecular Pathology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Walter Schmidt

Research Institute of Molecular Pathology

View shared research outputs
Researchain Logo
Decentralizing Knowledge